- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05329961
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Over a Four-year Follow up Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
Study Overview
Detailed Description
Study participants will include 150 boys and girls aged 4-8 years (total, 75 boys and 75 girls) to receive 2 doses of the 9vHPV vaccine at 0 and 12 months. Patients will be recruited by age-group to achieve balanced enrollment of 15 girls and 15 boys per year of age. The investigators will examine the immunogenicity profile in this cohort, for which titers will be analyzed one month after dose 2 (Month 13) and at Month 60.
Though clinical efficacy cannot be assessed in young children because of limited exposure to human papillomavirus (HPV), this descriptive study will allow the investigators to understand whether the 9vHPV vaccine in younger patients provides immunogenicity similar to that shown for the 9-14 and 16-26 age groups who have received the 9vHPV vaccine.13 This study will require an IND for the use of the HPV vaccine in children younger than 9 years.
Immunogenicity will be measured by examining serum antibodies of all participants using a competitive Luminex immunoassay (cLIA).15 Month 60 serology will be by cLIA and IgG LIA assays. The antibody response testing will be performed at Merck Research Laboratory.
The goal of this study is to explore whether a 2-dose 9vHPV vaccine regimen with dosage separated by 12 months is immunogenic among children aged 4-8 years. The primary outcome will be geometric mean titers (GMT) for HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58 antibodies at months 13 and 60. Results will allow the investigators to qualitatively compare immunogenicity in individuals vaccinated at age 4-8 years to known immunogenicity in 9vHPV recipients vaccinated at ages 9-14.13 Knowledge of whether vaccination in this age group is sufficient to induce high-level protective antibody titers through 4 years after the second dose will support further efficacy studies in a larger randomized trial of a 2-dose 9vHPV regimen for children aged 4-8 years.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Natalie Pierre-Joseph, MD
- Phone Number: 781-879-4841
- Email: napierre@bu.edu
Study Contact Backup
- Name: Johane Seide, MBA
- Phone Number: 617-414-5528
- Email: johane.seide@bmc.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston Medical Center
-
Contact:
- Natalie Pierre-Joseph, MD
- Phone Number: 781-879-4841
- Email: napierre@bu.edu
-
Contact:
- Johane Seide, MBA
- Phone Number: 617-414-5528
- Email: johane.seide@bmc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children aged 4-8 years old
- Receives care at the Boston Medical Center or one of the affiliated Community heath centers
- Naïve to HPV Vaccine
Exclusion Criteria:
- A history of severe allergic reaction, including known allergy to any vaccine component, specially severe allergic reaction to yeast
- Immunocompromised/previous immunosuppressive therapy
- Thrombocytopenia or other coagulation disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
HPV 9-valent human papillomavirus vaccine (Gardasil 9) - 0.5mL intramuscular dose - 2 doses (Month 0, 12)
|
The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP.
The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV6 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV6 if it is >30mMu.
|
13 months
|
HPV11 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV11 if it is >16mMu.
|
13 months
|
HPV16 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV16 if it is >20mMu.
|
13 months
|
HPV18 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV18 if it is >24 mMU.
|
13 months
|
HPV31 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV31 if it is >10 mMU.
|
13 months
|
HPV33 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV33 if it is >8 mMU.
|
13 months
|
HPV45 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV45 if it is >8 mMU.
|
13 months
|
HPV52 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV52 if it is >8 mMU.
|
13 months
|
HPV58 antibodies at 13 months
Time Frame: 13 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV58 if it is >8 mMU.
|
13 months
|
HPV6 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV6 if it is >30mMU.
|
60 months
|
HPV11 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV11 if it is >16 mMU.
|
60 months
|
HPV16 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV16 if it is >20 mMU.
|
60 months
|
HPV18 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV18 if it is >24mMU.
|
60 months
|
HPV31 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV31 if it is >10 mMU.
|
60 months
|
HPV33 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV33 if it is >8 mMU.
|
60 months
|
HPV45 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV45 if it is >8 mMU.
|
60 months
|
HPV52 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV52 if it is >8 mMU.
|
60 months
|
HPV58 antibodies at 60 months
Time Frame: 60 months
|
A serum sample will be analyzed using 9-valent Luminex immunoassay (cLIA, mMU/mL) to assess the geometric mean for HPV antibodies.
The results will be considered positive for HPV58 if it is >8 mMU.
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injection site swelling after first injection
Time Frame: day 3 after injection
|
Solicited local swelling will be graded from 0-4 where 0 is no swelling and 4 is severe swelling.
|
day 3 after injection
|
Injection site swelling after second injection
Time Frame: day 3 after injection
|
Solicited local swelling will be graded from 0-4 where 0 is no swelling and 4 is severe swelling.
|
day 3 after injection
|
Injection site redness after first injection
Time Frame: day 3 after injection
|
Solicited local redness will be graded from 0-4 where 0 is no redness and 4 is severe redness.
|
day 3 after injection
|
Injection site redness after second injection
Time Frame: day 3 after injection
|
Solicited local redness will be graded from 0-4 where 0 is no redness and 4 is severe redness.
|
day 3 after injection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Natalie Pierre-Joseph, MD, Boston Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-41686
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papilloma Virus
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLCCompletedCervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6United States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
The Behavioural Insights TeamUNICEF; National Center for Disease Control and Public Health, Georgia; Information...Not yet recruitingHPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
-
Universitair Ziekenhuis BrusselRecruiting
-
Xiamen Innovax Biotech Co., LtdZhejiang Provincial Center for Disease Control and PreventionActive, not recruitingHuman Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus InfectionChina
-
Universiti Sains MalaysiaRecruitingHuman Papilloma Virus InfectionMalaysia
-
Universiteit AntwerpenCompletedHuman Papilloma Virus InfectionBelgium
-
Gen-Probe, IncorporatedCompletedHuman Papilloma Virus InfectionUnited States
-
Shanghai Zerun Biotechnology Co.,LtdGuangxi Center for Disease Control and PreventionCompletedCervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
Clinical Trials on Gardasil9
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompleted
-
Miriam ElfströmKarolinska University HospitalRecruitingCervical Cancer | HPV Infection | CIN 2/3Sweden
-
Merck Sharp & Dohme LLCActive, not recruitingPapillomavirus InfectionsChina
-
Fundacion SEIMC-GESIDAMerck Sharp & Dohme LLCCompleted
-
Johns Hopkins UniversityMerck Sharp & Dohme LLCCompletedHPV | Human Papilloma Virus | ImmunizationUnited States
-
University of British ColumbiaRecruitingHuman Immunodeficiency Virus | HPV | Human Papilloma VirusCanada
-
Universitaire Ziekenhuizen KU LeuvenCompletedHiv | Human Papilloma Virus | Organ TransplantsBelgium
-
University of British ColumbiaMerck Canada Inc.CompletedHuman PapillomavirusCanada
-
London School of Hygiene and Tropical MedicineNational Cancer Institute (NCI); Karolinska Institutet; Institut Català d'Oncologia and other collaboratorsActive, not recruitingHuman Papilloma VirusTanzania